L. B. Laffel

Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial

M. Wheeler, N. Dixit, W. Tamborlane, 2023, The Lancet Diabetes & Endocrinology.

Type 2 diabetes, obesity, and the renal response to blocking the renin system with irbesartan

N. Hollenberg, L. Laffel, M. Lansang, 2002, Diabetic medicine : a journal of the British Diabetic Association.

Evolving natural history of coronary artery disease in diabetes mellitus.

A. Krolewski, L. Laffel, J. Warram, 1991, The American journal of medicine.

Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus.

N. Hollenberg, L. Laffel, B. Perkins, 2003, Kidney international.

Predisposition to hypertension and susceptibility to renal disease in insulin-dependent diabetes mellitus.

W. Knowler, L. Rand, A. Krolewski, 1988, The New England journal of medicine.